Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Exclusion Criteria

• •1. Patients undergoing implantation of the CODMAN CERTAS Plus Programmable Valve as a revision procedure.
• •2. Patient's planned shunt has distal drainage to the heart.
• •3. Patient has ventriculitis, peritonitis or meningitis.
• •4. Patient has sepsis.
• •5. Patient has a history of poor wound healing.
• •6. Patient has symptoms pertaining to a skin infection at or near the site of any incisions; an ear infection on either side; a respiratory tract infection; or a urinary tract infection that, in the Investigator's opinion is clinically significant and might compromise the outcome of this study.
• •7. Patient has had any form of bowel surgery 30 days prior to device implant or anticipates bowel surgery within 90 days following device implant.
• •8. Patient is otherwise determined by the Investigator to be medically unsuitable for participation in this study.
• •9. Patient is currently enrolled in another drug or device trial or has been previously entered in this trial.
• •10. Patient is a prisoner or member of a different vulnerable population that should not be included in the study per the investigator.
• •11. Patients with known hypersensitivity to rifampin or clindamycin hydrochloride. This criterion applies for patients to be treated with the BACTISEAL Catheters (included in some models of the valve) only.